CSIMarket
 
Cti Biopharma Corp   (CTIC)
Other Ticker:  
 
 
Price: $9.0900 $0.00 0.000%
Day's High: $9.1 Week Perf: 0.22 %
Day's Low: $ 9.09 30 Day Perf: 1.11 %
Volume (M): 11,421 52 Wk High: $ 9.10
Volume (M$): $ 103,816 52 Wk Avg: $6.64
Open: $9.10 52 Wk Low: $4.01



 Market Capitalization (Millions $) 1,196
 Shares Outstanding (Millions) 132
 Employees -
 Revenues (TTM) (Millions $) 76
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) -38
 Capital Exp. (TTM) (Millions $) 25

Cti Biopharma Corp
CTI Biopharma Corp is a biopharmaceutical company that focuses on the development and commercialization of targeted therapies for blood-related cancers. The company is engaged in researching treatments for these types of cancers, including myeloproliferative neoplasms and leukemia. CTI Biopharma Corp's pipeline includes investigational drugs that aim to address unmet medical needs in these areas. The company is dedicated to improving the lives of cancer patients through innovative therapies and advancing scientific knowledge in the field of oncology.


   Company Address: 3101 Western Avenue Seattle 98121 WA
   Company Phone Number: 282-7100   Stock Exchange / Ticker: NASDAQ CTIC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cti Biopharma Corp

Cti Biopharma Corp Reports Financial Improvements in Recent Quarter, but Lingering Losses Raise Concerns for Investors

Cti Biopharma Corp (CTIC) seems to have reported some financial improvements in their previous quarter end results, but unfortunately, the picture is not as rosy as it seems for investors to be bullish on the company. With the persistent losses and negligible earnings growth, the company has yet to make any significant progress towards profitability.
Looking at CTIC's financials for the quarter ending March 31, 2023, the company slashed its net loss per share to $-0.10 from last year's $-0.37, which may at first glance appear as a win for the company. However, investors must note that a reduced loss per share does not necessarily mean that the company is doing well. The reality is that the company's operations are not generating substantial profits, leading to the continuing losses.






 

Cti Biopharma's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com